嵌合抗原受体
医学
淋巴母细胞淋巴瘤
淋巴瘤
淋巴细胞白血病
肿瘤科
限制
危险分层
T细胞
疾病
挽救疗法
硼替佐米
耐火材料(行星科学)
内科学
癌症研究
白血病
免疫学
化疗
癌症
免疫疗法
生物
多发性骨髓瘤
免疫系统
工程类
天体生物学
机械工程
作者
Ryan M. Summers,David T. Teachey
标识
DOI:10.1016/j.clml.2022.07.010
摘要
While outcomes for children with T-cell acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LL) have improved significantly with contemporary therapy, outcomes for patients with relapsed or refractory (r/r) disease remain dismal. Improved risk stratification and the incorporation of novel therapeutics have the potential to improve outcomes further in T-ALL/T-LL by limiting relapse risk and improving salvage rates for those with r/r disease. In this review we will discuss the challenges and new opportunities for improved risk stratification in T-ALL and T-LL. We will further discuss the recent incorporation of the novel therapeutics nelarabine and bortezomib into front-line therapy for children with T-ALL and T-LL. Finally, we will address new classes of targeted small molecule inhibitors, immunotherapeutics, and chimeric antigen receptor T-cell therapies under investigation in r/r T-ALL and T-LL.
科研通智能强力驱动
Strongly Powered by AbleSci AI